natgillin/translations-raw huggingface dataset:
As stated earlier, the Applicant provided initial repriming studies on the test product which were complemented with a repriming study with the reference product and the CHMP considered that while the data demonstrate the effect of the position of the MDI on the deposited dose, this effect is observed in both the test and the reference product. 
Kot je bilo že ugotovljeno, je predlagatelj predložil začetne študije ponovnega polnjenja testnega zdravila, ki jih je dopolnil s študijo ponovnega polnjenja z referenčnim zdravilom, odbor CHMP pa je menil, da je kljub dokazanemu vplivu položaja inhalatorja na odmerjeni odmerek ta vpliv na odložen odmerek opazen tako pri testnemu kot tudi referenčnemu zdravilu.
The Applicant was able to present data from the pulmonary deposition study (Study 200776-DOS-6) were presented and interpreted and this new in vitro data (without spacer in a normal and humid environment and with spacer in a normal environment) suggested a similar particle size distribution between the test and the reference product. 
Predstavil in obrazložil je podatke iz študije odlaganja v pljučih (študija 2007-76-DOS-6), ti novi in vitro podatki (brez uporabe podaljška v normalnem in vlažnem okolju in z uporabo podaljška v normalnem okolju) pa nakazujejo na enako porazdelitev velikosti delcev tako pri testnem kot tudi referenčnem zdravilu.
The Applicant stated that the presented in vitro data can be predictive of pharmacokinetic bioequivalence for Cmax and for peak airway and systemic beta-2 adrenoceptor mediated responses, which are mainly determined by lung bioavailability. 
Predlagatelj je izjavil, da lahko predstavljeni in vitro podatki nakazujejo na farmakokinetično biološko enakovrednost za Cmax in za največje odzive dihalnih poti in odzive, ki jih mediirajo sistemski beta-2-adrenoceptorji, kar v glavnem določa biološka razpoložljivost v pljučih.
The amount of salbutamol impacted on stages comprising throat/0/1/2 are non respirable (i.e. >4.7 µm) and will correspond to larger particles deposited on the oropharynx (throat stage) and upper airway (stages 0/1/2). 
Količine salbutamola, zaustavljene na stopnjah, ki obsegajo 0., 1. in 2. stopnjo grla, ni mogoče vdihniti (tj. delci večji od 4,7 µm), in ustrezajo večjim delcem, ki se nalagajo na mezofarinks (stopnja grla) in v zgornjih dihalnih poteh (0., 1. in 2. stopnja).
In conclusion, the CHMP considered that the Applicant responses to the List of Outstanding Issues did allow the committee to conclude that the test and the reference product are similar when used without a spacer, with regards to safety aspects. 
Odbor CHMP je menil, da lahko na podlagi odgovorov predlagatelja na seznam nerešenih vprašanj pride do zaključka, da sta testno in referenčno zdravilo, kar zadeva varnost, podobni pri uporabi brez podaljška.
The pharmacokinetic bioequivalence study also confirmed that both products possess the same systemic safety profile since bioequivalence in systemic levels (AUC and Cmax) have been shown. 
Farmakokinetična študija biološke enakovrednosti je potrdila tudi, da imata obe zdravili enak profil sistemske varnosti, saj je bila dokazana biološka enakovrednost na sistemskih ravneh (AUC in Cmax).
Although the claim of the Applicant that the PK bioequivalence study demonstrated equivalence without spacer was endorsed, the CHMP did not support the assumption that the data with the use of a spacer would provide the same evidence of equivalence and therefore considered that a PK study with a spacer is mandatory. 
Čeprav je odbor CHMP sprejel trditev predlagatelja, da je farmakokinetična študija biološke enakovrednosti dokazala enakovrednost brez uporabe podaljška, pa ni mogel podpreti predpostavke, da bi podatki ob uporabi podaljška pomenili enak dokaz enakovrednosti, zato je menil, da je farmakokinetična študija o uporabi podaljška obvezna.
- the CHMP considered that Sabumalin and the reference product possess the same systemic safety profile, as demonstrated by the bioequivalence in systemic levels (AUC and Cmax), 
- CHMP je menil, da imata zdravilo Sabumalin in referenčno zdravilo enak profil sistemske varnosti, kot je bilo dokazano z biološko enakovrednostjo na sistemskih ravneh (AUC in Cmax),
For stages representing extra fine particles (<1.1µm), equivalence was also shown, with the exception of deposition in the filter stage (outside +15% but within +20%). 
Enakovrednost je bila dokazana tudi za stopnje, ki predstavljajo posebej drobne delce (manjše od 1,1µm), z izjemo odlaganja v filtrirni stopnji (zunaj ±15 %, vendar znotraj ±20 %).
However, equivalence between the test and reference products has still not been fully demonstrated although this may be addressed by submitting an analysis of the data from the ongoing study 2007-76-DOS-6, the CHMP addressed two outstanding issues to be discussed by the Applicant during an oral explanation: 
Vendar enakovrednost testnega in referenčnega zdravila še vedno ni bila popolnoma dokazana, čeprav lahko predlagatelj na to odgovori s predložitvijo analize podatkov iz tekoče študije 2007-76-DOS-6.
a. Why the comparison of all the individual stages is not more discriminative to detect differences between formulations that may have clinical relevance b. Why the particles of 6 µm or up to 8 µm, which are deposited in stage 1, are considered with regards to safety only. 
b. Zakaj se delci velikosti 6 µm ali do 8 µm, ki se odlagajo na 1. stopnji, obravnavajo le glede na varnost?
The Applicant concluded that the in vitro data and the negligible clinical relevance of the differences detected were supported by the provided in vivo study. 
Predlagatelj je zaključil, da predložena študija in vivo podpira podatke in vitro in zanemarljiv klinični pomen odkritih razlik.
The pharmacokinetic bioequivalence data also confirmed that Sabumalin and the reference product possess the same systemic safety profile since bioequivalence in systemic levels (AUC and Cmax) have been shown, when used with or without a spacer. 
Farmakokinetični podatki o biološki enakovrednosti so prav tako potrdili, da imata zdravilo Sabumalin in referenčno zdravilo, ob uporabi podaljška ali brez njega, enak profil sistemske varnosti, saj je bila dokazana biološka enakovrednost na sistemskih ravneh (AUC in Cmax).
SalbuLEK 
Jakost
presción EFG 
Nemčija pressurizzata per
Invented name Strength Pharmaceutical form Route of administration Packaging 
Farmacevtska oblika
The European Commission granted a marketing authorisation valid throughout the European Union for Orbactiv on 19 March 2015. 
Evropska komisija je dovoljenje za promet z zdravilom Orbactiv, veljavno po vsej Evropski uniji, izdala 19. marca 2015.
What measures are being taken to ensure the safe and effective use of Orbactiv? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Orbactiv?
The full EPAR and risk management plan summary for Orbactiv can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Orbactiv sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
These also included infections caused by MRSA. 
Med njimi so bile tudi okužbe, ki jih povzroča bakterija MRSA.
The recommended dose is a single infusion of 1,200 mg over three hours. 
Priporočeni odmerek je 1 200 mg v obliki ene 3-urne infuzije.
The study also looked at the number of patients whose infection was cured after treatment. 
V študijah so merili tudi število bolnikov, pri katerih je bila okužba po zdravljenju ozdravljena.
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Orbactiv's benefits are greater than its risks and recommended that it be approved for use in the EU. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Orbactiv večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
It works by preventing certain bacteria from making their own cell walls, thereby killing the bacteria. 
Deluje tako, da prepreči, da bi si določene bakterije zgradile celične stene, s čimer bakterije uniči.
This is a summary of the European public assessment report (EPAR) for Orbactiv. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Orbactiv.
In both studies, the main measure of effectiveness was the number of patients who responded within 3 days of starting treatment with an improvement in their skin in the infected area, lack of fever and no need for additional antibiotic. 
V obeh študijah je bilo glavno merilo učinkovitosti število bolnikov, ki so se v treh dneh po začetku zdravljenja nanj odzvali z izboljšanjem kože na okuženem območju ter odsotnostjo povišane telesne temperature in potrebe po dodatnih antibiotikih.
Other information about Orbactiv 
Druge informacije o zdravilu Orbactiv
A risk management plan has been developed to ensure that Orbactiv is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Orbactiv je bil pripravljen načrt obvladovanja tveganj.
What benefits of Orbactiv have been shown in studies? 
Kakšne koristi je zdravilo Orbactiv izkazalo v študijah?
In addition, 82.7% of patients treated with Orbactiv in the first study and 79.6% in the second study were cured, compared with 80.5% and 80.0% respectively of patients treated with vancomycin. 
Poleg tega je bilo v prvi študiji ozdravljenih 82,7 % bolnikov, zdravljenih z zdravilom Orbactiv, v drugi študiji pa 79,6 %, v primerjavi z 80,5 oziroma 80,0 % bolnikov, zdravljenih z vankomicinom.
What is Orbactiv and what is it used for? 
Kaj je zdravilo Orbactiv in za kaj se uporablja?
The CHMP considered that these side effects were manageable and adequately addressed in the product information. 
Menil je, da so ti neželeni učinki obvladljivi in da so ustrezno obravnavani v informacijah o zdravilu.
Why is Orbactiv approved? 
Zakaj je bilo zdravilo Orbactiv odobreno?
The active substance in Orbactiv, oritavancin, is a type of antibiotic called a glycopeptide. 
Zdravilna učinkovina v zdravilu Orbactiv, oritavancin, je vrsta antibiotika, ki se imenuje glikopeptid.
Orbactiv has been shown to work against bacteria (such as methicillin resistant Staphylococcus aureus (MRSA)) for which standard antibiotics do not work. 
Zdravilo Orbactiv je dokazano učinkovito proti bakterijam (na primer proti na meticilin odporni bakteriji Staphylococcus aureus (MRSA)), proti katerim običajni antibiotiki ne delujejo.
What are the risks associated with Orbactiv? 
Kakšna tveganja so povezana z zdravilom Orbactiv?
Before using Orbactiv, doctors should consider official guidance on the appropriate use of antibiotics. 
Preden zdravnik predpiše zdravilo Orbactiv, mora pretehtati njegovo uporabo glede na uradne smernice za ustrezno uporabo antibiotikov.
The most common side effects with Orbactiv (which may affect 5 people or more in 100) are nausea (feeling sick), hypersensitivity (allergy) reactions or reactions at the site of infusion and headache. 
Najpogostejši neželeni učinki zdravila Orbactiv (ki lahko prizadenejo 5 ali več oseb od 100) so navzeja (slabost), preobčutljivostne (alergijske) reakcije ali reakcije na mestu infundiranja ter glavobol.
The most common side effects that resulted in treatment being stopped were cellulitis and osteomyelitis (bone infection). 
Najpogostejša neželena učinka, ki sta privedla do prekinitve zdravljenja, sta bila celulit in osteomielitis (okužba kosti).
It is not intended to provide practical advice on how to use Orbactiv. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
It contains the active substance oritavancin. 
Vsebuje zdravilno učinkovino oritavancin.
Although Orbactiv's safety profile overall is similar to that of other glycopeptides, the CHMP noted that some side effects occurred more frequently such as abscesses and bone infections. 
Čeprav je varnostni profil zdravila Orbactiv na splošno podoben varnostnemu profilu drugih glikopeptidov, je odbor CHMP opozoril, da se nekateri neželeni učinki, kot so abscesi in kostne okužbe, pojavljajo pogosteje.
For the full list of all side effects and restrictions with Orbactiv, see the package leaflet. 
Za celoten seznam vseh neželenih učinkov in omejitev pri uporabi zdravila Orbactiv glejte navodilo za uporabo.
Orbactiv was at least as effective as vancomycin at treating the infection: 80.1% of patients treated with Orbactiv in the first study and 82.3% in the second study responded to treatment, compared with 82.9% and 78.9% respectively of patients treated with vancomycin. 
Zdravilo Orbactiv je bilo pri zdravljenju okužbe vsaj tako učinkovito kot vankomicin: v prvi študiji se je na zdravljenje odzvalo 80,1 % bolnikov, zdravljenih z zdravilom Orbactiv, v drugi študiji pa 82,3 %, v primerjavi z 82,9 oziroma 78,9 % bolnikov, zdravljenih z vankomicinom.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Orbactiv, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti tega zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
A list of bacteria against which Orbactiv is active can be found in the summary of product characteristics (also part of the EPAR). 
Seznam bakterij, proti katerim je zdravilo Orbactiv učinkovito, je na voljo v povzetku glavnih značilnosti zdravila (ki je prav tako del EPAR).
Orbactiv, given as a single infusion, was compared with a 7 to 10-day treatment with vancomycin (another glycopeptide) in two main studies involving a total of around 1,959 patients with acute bacterial infections of the skin and of skin structures, such as cellulitis, skin abscesses and wound infections. 
Zdravilo Orbactiv v obliki ene infuzije so primerjali s 7- do 10-dnevnim zdravljenjem z vankomicinom (drugim glikopeptidom) v dveh glavnih študijah, v kateri je bilo vključenih skupno približno 1 959 bolnikov z akutnimi bakterijskimi okužbami kože in kožnih struktur, kot so celulit, kožni abscesi in okužbe ran.
For more information about treatment with Orbactiv, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Orbactiv preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The CHMP considered that Orbactiv, which can be given as a single dose, could be a valuable alternative treatment option for acute bacterial infections of the skin and of skin structures. 
Menil je, da bi zdravilo Orbactiv, ki se lahko daje v enkratnem odmerku, lahko bilo dragocena druga možnost zdravljenja bakterijskih okužb kože in kožnih struktur.
Patients who have received Orbactiv must not be given an infusion of unfractionated heparin (a medicine used to prevent blood clots) for 120 hours after the infusion of Orbactiv. 
Bolnikom, ki so prejeli zdravilo Orbactiv, se še vsaj 120 ur po infuziji tega zdravila ne sme infundirati nefrakcioniranega heparina (zdravila za preprečevanje krvnih strdkov).
Orbactiv is an antibiotic used in adults to treat acute (short-term) bacterial infections of the skin and of skin structures (tissue below the skin) such as cellulitis (inflammation of the deep skin tissue), skin abscesses and wound infections. 
Zdravilo Orbactiv je antibiotik, ki se uporablja pri odraslih za zdravljenje akutnih (kratkotrajnih) bakterijskih okužb kože in kožnih struktur (podkožnega tkiva), kot so celulit (vnetje globokega podkožnega tkiva), kožni abscesi in okužbe ran.
For practical information about using Orbactiv, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Orbactiv naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Orbactiv is available as a powder to be made up into a solution for infusion (drip) into a vein and can only be obtained with a prescription. 
Zdravilo Orbactiv je na voljo v obliki praška za pripravo raztopine za infundiranje (kapalne infuzije) v veno in se izdaja le na recept.
How is Orbactiv used? 
Kako se zdravilo Orbactiv uporablja?
How does Orbactiv work? 
Kako zdravilo Orbactiv deluje?
Week 1 
Teden 1
Date of latest renewal: 22 May 2014 
Datum zadnjega podaljšanja dovoljenja za promet: 22 maj 2014
• You should tell your doctor if a surgery (including dental) is planned. 
• morate zdravniku povedati, če imate predvideno kakšno operacijo (tudi zobozdravstveni poseg);
Secondary prevention of atherothrombotic events 
Sekundarno preprečevanje aterotrombotičnih dogodkov
An occasional use of acetylsalicylic acid (no more than 1,000 mg in any 24 hour period) should generally not cause a problem, but prolonged use in other circumstances should be discussed with your doctor. 
Priložnostna uporaba acetilsalicilne kisline (ne več kot 1.000 mg v katerem koli 24 urnem obdobju) na splošno ne bi smela povzročati težav, vendar pa se morate o daljši uporabi v drugih okoliščinah posvetovati z zdravnikom.
Clopidogrel has been evaluated for safety in more than 44,000 patients, who have participated in clinical studies, including over 12,000 patients treated for 1 year or more. 
Varnost klopidogrela so vrednotili pri več kot 44.000 bolnikih, ki so sodelovali v kliničnih študijah, vključno z več kot 12.000 bolniki, ki so se zdravili eno leto ali več.
• if you are allergic to clopidogrel or any of the other ingredients of this medicine (listed in section 6); 
• če ste alergični na klopidogrel ali katero koli sestavino tega zdravila (navedeno v poglavju 6);
Their frequency is defined using the following conventions: common (1/100 to <1/10); uncommon (1/1,000 to < 1/100); rare (1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data). 
Njihova pogostnost je navedena po naslednjem dogovoru: pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000), neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti).
Some other medicines may influence the use of Clopidogrel Mylan or vice versa. 
Nekatera druga zdravila lahko vplivajo na jemanje zdravila Klopidogrel Mylan in obratno.
The results obtained in populations with different characteristics (e.g. unstable angina or non-Q-wave MI, low to high risk levels, diabetes, need for revascularisation, age, gender, etc.) were consistent with the results of the primary analysis. 
Rezultati, pridobljeni pri populacijah z različnimi karakteristikami (npr. nestabilna angina, MI brez Q zobca, visoka do nizka raven tveganja, diabetes, potreba po revaskularizaciji, spol, starost, itd), so skladni z rezultati primarne analize.
CYP2C8 substrates 
Substari CYP2C8
In patients suffering from acute coronary syndrome: 
Pri bolnikih z akutnim koronarnim sindromom:
7 film-coated tablets 14 film-coated tablets 28 film-coated tablets 30 film-coated tablets 30x1 film-coated tablets 50 film-coated tablets 50x1 film-coated tablets 56 film-coated tablets 84 film-coated tablets 90 film-coated tablets 100 film-coated tablets 
7 filmsko obloženih tablet 14 filmsko obloženih tablet 28 filmsko obloženih tablet 30 filmsko obloženih tablet 30x1 filmsko obloženih tablet 50 filmsko obloženih tablet 50x1 filmsko obloženih tablet 56 filmsko obloženih tablet 84 filmsko obloženih tablet 90 filmsko obloženih tablet 100 filmsko obloženih tablet
If you experience prolonged bleeding when taking Clopidogrel Mylan If you cut or injure yourself, it may take longer than usual for bleeding to stop. 
Če doživite podaljšanje krvavitve v času jemanja zdravila Klopidogrel Mylan Če se urežete ali poškodujete, lahko traja dlje kot običajno, da se krvavitev ustavi.
You should take Clopidogrel Mylan for as long as your doctor continues to prescribe it. 
Zdravilo Klopidogrel Mylan morate jemati, dokler vam ga zdravnik predpisuje.
Pink, round and biconvex film-coated tablets. 
Rožnate, okrogle in bikonveksne filmsko obložene tablete.
The patient population included 19.7% women and 29.2% patients ≥ 65 years. 
Populacijo bolnikov je sestavljalo 19,7 % žensk in 29,2 % bolnikov v starosti ≥ 65 let.
Published frequencies for the poor CYP2C19 metaboliser genotypes are approximately 2% for Caucasians, 4% for Blacks and 14% for Chinese. 
Objavljene pogostnosti genotipa slabega metabolizatorja s CYP2C19 so približno 2 % pri Kavkazijcih, 4 % pri črncih in 14 % pri Kitajcih.
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/ 
<Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu/
You should have been told that ‘oral anticoagulants' are more effective than acetylsalicylic acid or the combined use of Clopidogrel Mylan and acetylsalicylic acid for this condition. 
Povedati so vam morali, da so "peroralni antikoagulanti" pri tej motnji učinkovitejši kot acetilsalicilna kislina ali kombinirana uporaba zdravila Klopidogrel Mylan in acetilsalicilne kisline.
The active metabolite is formed mostly by CYP2C19 with contributions from several other CYP enzymes, including CYP1A2, CYP2B6 and CYP3A4. 
Aktivni presnovek se tvori pretežno s CYP2C19 in prispevkom nekaterih ostalih CYP encimov, vključno s CYP1A2, CYP2B6 in CYP3A4.
Patients were required to have either ECG changes compatible with new ischaemia or elevated cardiac enzymes or troponin I or T to at least twice the upper limit of normal. 
Bolniki so morali imeti bodisi spremembe elektrokardiograma (EKG), združljive z novo ishemijo, ali povišane srčne encime ali troponin I ali T na najmanj dvakratno zgornjo mejo normalnega.
Warnings and precautions Talk to your doctor before taking Clopidogrel Mylan if any of the situations mentioned below apply to you: 
Opozorila in previdnostni ukrepi Preden boste vzeli zdravilo Klopidogrel Mylan morate obvestiti zdravnika, če se katerokoli od spodaj navedenih stanj nanaša na vas:
C-labelled clopidogrel in man, approximately 50% was excreted in the urine and approximately 46% in the faeces in the 120-hour interval after dosing. 
C-označenega klopidogrela pri človeku, se ga je približno 50 % izločilo z urinom in približno 46 % z blatom v 120 urnem intervalu po odmerjanju.
In COMMIT, the overall rate of noncerebral major bleeding or cerebral bleeding was low and similar in both groups. 
V študiji COMMIT je bil skupni delež večjih necerebralnih krvavitev ali cerebralne krvavitve majhen in podoben v obeh skupinah.
As no clinical data on exposure to clopidogrel during pregnancy are available, it is preferable not to use clopidogrel during pregnancy as a precautionary measure. 
Ker kliničnih podatkov o izpostavljenosti klopidogrelu med nosečnostjo ni, je kot previdnostni ukrep zaželeno, da se klopidogrela me nosečnostjo ne uporablja.
Then, the recommended dose is one 75 mg tablet of Clopidogrel Mylan per day as described above. 
Nato je priporočeni odmerek ena 75 mg tableta zdravila Klopidogrel Mylan na dan, kot je opisano zgoraj.
The population included 27.8% women, 58.4% patients ≥ 60 years (26% ≥ 70 years) and 54.5% patients who received fibrinolytics. 
Populacijo bolnikov je sestavljalo 27,8 % žensk, 58,4 % bolnikov starost ≥ 60 let (26 % ≥ 70 let ) in 54,5 % bolnikov, ki so dobivali fibrinolitike.
• if you have had a clot in an artery of your brain (ischaemic stroke) which occurred within the last seven days. 
• če ste imeli strdek v možganski arteriji (ishemična kap), ki se je pojavil v zadnjih sedmih dneh;
The efficacy of clopidogrel was observed independently of the dose of ASA (75-325 mg once daily). 
Učinkovitost klopidogrela so opazili neodvisno od odmerka ASA (75-325 mg enkrat na dan).
Your doctor should have prescribed Clopidogrel Mylan plus acetylsalicylic acid if you cannot take ‘oral anticoagulants' and you do not have a risk of major bleeding. 
Zdravnik naj bi vam predpisal zdravilo Klopidogrel mylan skupaj z acetilsalicilno kislino, če ne morete prejemati "peroralnih antikoagulantov", ali če nimate tveganja za večjo krvavitev.